Fluticasone Salmeterol
Total Payments
$24.0M
Transactions
1,074
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.2M | 176 | 0 |
| 2019 | $16.7M | 672 | 2 |
| 2018 | $5.1M | 225 | 1 |
| 2017 | $197.10 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $24.0M | 1,074 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study | Hikma Pharmaceuticals USA | $16.7M | 2 |
| Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study | West-Ward Pharmaceuticals | $5.1M | 1 |
| Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study | Hikma Pharmaceuticals USA | $2.2M | 0 |
| FLSA Clinical Endpoint Bioequivalence Study | West-Ward Pharmaceuticals | $197.10 | 0 |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $18.9M
- West-Ward Pharmaceuticals $5.1M
Product Information
- Type Drug
- Total Payments $24.0M
- Total Doctors 2
- Transactions 1,074
About Fluticasone Salmeterol
Fluticasone Salmeterol is a drug associated with $24.0M in payments to 2 healthcare providers, recorded across 1,074 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2017 to 2020. In 2020, $2.2M was paid across 176 transactions to 0 doctors.
The most common payment nature for Fluticasone Salmeterol is "Unspecified" ($24.0M, 100.0% of total).
Fluticasone Salmeterol is associated with 4 research studies, including "Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study" ($16.7M).